Merck & Co PT Raised to $64.00 at MKM Partners (MRK)
Research analysts at MKM Partners hoisted their price objective on shares of Merck & Co (NYSE:MRK) from $59.00 to $64.00 in a report released on Tuesday, American Banking and Market News reports. The firm currently has a “buy” rating on the stock. MKM Partners’ price target would suggest a potential upside of 20.75% from the stock’s previous close.
MRK has been the subject of a number of other recent research reports. Analysts at TheStreet reiterated a “buy” rating on shares of Merck & Co in a research note to investors on Monday. Separately, analysts at Jefferies Group raised their price target on shares of Merck & Co from $51.00 to $54.00 in a research note to investors on Thursday, January 9th. They now have a “hold” rating on the stock. Finally, analysts at Zacks reiterated a “neutral” rating on shares of Merck & Co in a research note to investors on Tuesday, December 31st. They now have a $52.00 price target on the stock. Two investment analysts have rated the stock with a sell rating, six have given a hold rating and seven have assigned a buy rating to the company. The stock has an average rating of “Hold” and a consensus target price of $52.60.
Merck & Co (NYSE:MRK) traded down 0.23% during mid-day trading on Tuesday, hitting $53.00. The stock had a trading volume of 21,190,840 shares. Merck & Co has a 52-week low of $40.83 and a 52-week high of $53.44. The stock has a 50-day moving average of $49.60 and a 200-day moving average of $48.04. The company has a market cap of $154.9 billion and a P/E ratio of 35.70. Merck & Co also saw some unusual options trading activity on Monday. Traders acquired 32,843 call options on the stock. This represents an increase of 294% compared to the average volume of 8,326 call options.
Merck & Co (NYSE:MRK) last released its earnings data on Monday, October 28th. The company reported $0.92 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.88 by $0.04. The company had revenue of $11.03 billion for the quarter, compared to the consensus estimate of $11.19 billion. During the same quarter in the prior year, the company posted $0.95 earnings per share. The company’s quarterly revenue was down 4.0% on a year-over-year basis. Analysts expect that Merck & Co will post $3.50 EPS for the current fiscal year.
Merck & Co, Inc (NYSE:MRK) is a global health care company that delivers health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products, which it markets directly and through its joint ventures.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.